Evolving Treatment Strategies in the Management of Acute Myeloid Leukemia (AML): Individualized Therapy for Improved Clinical and Economic Outcomes

A continuing medical education activity provided by NAMCP and AAMCN

This activity is an archive from the live session from the 2020 Fall Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from January 1, 2021 to January 1, 2022

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This activity is supported by educational grants from
Astellas and Bristol-Myers Squibb

Description:
Acute myeloid leukemia (AML) is a cancer of the myeloid line of blood cells, characterized by the rapid growth of abnormal white blood cells that build up in the bone marrow and interfere with the production of normal blood cells. AML is the most common acute leukemia affecting adults, and its incidence increases with age. Although AML is a relatively rare disease, accounting for roughly 1.2% of cancer deaths in the United States, its incidence is expected to increase as the population ages. The American Cancer Society estimates that there were approximately 21,380 new cases of AML and 10,590 deaths from AML in the United States in 2019. The five-year survival rate has not improved in older patients despite of 40 years of research. Fortunately for patients with AML, many new treatments are are now here or are on the horizon. New options, which have the ability to target certain types of mutations, have been approved in AML for the first time since 1990. With so many new options becoming available in the next few years, the treatment paradigm in AML, especially in relapsed or refractory disease, is set to drastically change. With that change comes a knowledge gap among physician medical directors, oncologists, practicing physicians and nurses. For this reason, it is critical that these HCPs are educated and updated on these emerging options and strategies for their implementation into the treatment paradigm, which will ultimately improve patient outcomes in the AML patient population.

AML has several subtypes and treatment and prognosis vary among subtypes. After AML has been diagnosed, tests are done to find out the subtype. This is especially important, as several new treatments focus on AML disease with certain mutations, including FLT3. Following older treatment paradigms, AML has been cured in 35-40% of people under 60 years old, but only in 5-15% of people over 60 years old. Fortunately for patients with AML, that treatment paradigm has begun to dramatically change, as novel targeted agents have shown improved efficacy and safety outcomes in recent clinical data. It is imperative that physician medical directors, oncologists, practicing physicians, nurse case managers and other healthcare professionals are brought up to date regarding this new data in these novel treatments, as one has already become available and more options are set to follow.

Upon completion of this activity, participants will be able to:

  • Examine the clinical and economic burden of acute myeloid leukemia (AML), including factors that contribute to poor prognosis and increased costs

  • Analyze the efficacy, safety and mechanisms of action of novel therapeutics in AML in a range of patient populations

  • Explore the evolving role of maintenance therapy for patients with AML in first remission

  • Examine the role of mutation analysis in appropriate patient selection for targeted treatment strategies

  • Interpret recent clinical trial data evaluating the efficacy and safety of treatments targeting FLT3, IDH1/2, and BCL-2

  • Employ interventions such as clinical pathways and site of care initiatives for optimal cost management and improved outcomes in AML

     

Faculty: Amir T. Fathi, MD
Director, Leukemia Program
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School

Disclosure:

Dr. Fathi serves as a consultant for AbbVie, Agios, Amgen, Astellas, Blueprint, Celgene/BMS, Kura, Pfizer, Seattle Genetics, Takeda, and Trillium. He has received grant/research support from Agios and Celgene/BMS. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no real or perceived financial relationships to disclose.
Jeremy Williams has no real or perceived financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no real or perceived financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in nursing continuing professional development.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This activity is supported by educational grants from
Astellas and Bristol-Myers Squibb

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue